Ambetter denied your biologics? What to do next

Why Centene / Ambetter denies biologic and infusion therapy

Centene operates one of the largest Medicaid footprints in the U.S. and sells ACA marketplace coverage under the Ambetter brand. Marketplace plans drew elevated regulator and journalist scrutiny in 2024 for higher-than-average denial rates on in-network claims, and Centene-managed Medicaid lines vary plan-by-plan by state.

For biologic and infusion therapy specifically: Biologics such as adalimumab, infliximab, vedolizumab, ustekinumab, and rituximab are denied at prior authorization for step-therapy, missing labs, or diagnosis mismatch, and later for site of care or dose escalation. The appeal is a documentation exercise against the plan's own criteria.

The law that controls this appeal

Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).

What Centene / Ambetter denies for biologic and infusion therapy

The biologic and infusion therapy services most often denied:

First biologic for Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, or psoriasis
Switch to a second biologic after the first stops working
Dose escalation or interval shortening beyond the label
Infusion at a hospital outpatient department instead of home or a standalone center
Biosimilar substitution disputes

Why biologic and infusion therapy claims get denied

A typical Centene / Ambetter biologic and infusion therapy denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Step therapy: conventional drugs (methotrexate, mesalamine, steroids) not tried or not documented
Disease activity scores or lab markers missing from the record
Diagnosis code does not match the labeled indication
TB or hepatitis B screening not on file
Plan prefers a different biologic or a biosimilar first

The Centene / Ambetter appeal process

Appeal levels: Marketplace: internal appeal then federal external review (IRO). Medicaid: plan appeal then state fair hearing. Medicare Advantage: federal 5-level ladder.

Carrier timing: 180 days from denial for marketplace internal appeals; 4 months / 120 days for federal external review. Medicaid fair-hearing deadlines vary by state, often as short as 90-120 days.

Biologics timing: Untreated inflammatory disease supports an expedited appeal: decision within 72 hours. Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D. External review: within 4 months of the final internal denial for ACA-covered plans (45 CFR 147.136).

What we know about Centene / Ambetter: We confirm the specific Centene subsidiary (Ambetter, Sunshine Health, Wellcare, etc.) before filing, because procedural rules and the supervising regulator change with the line of business.

Common Centene / Ambetter denial patterns for biologic and infusion therapy

ACA marketplace in-network denials. Ambetter marketplace plans have been documented denying in-network medical claims at rates above the marketplace average. Federal ACA rules guarantee internal appeal plus external review via an Independent Review Organization (IRO), both are no-cost to the member.
Narrow networks driving care-access denials. Ambetter HMO products often run narrower networks than the local competition. Network-adequacy challenges (state DOI complaints citing inadequate specialist access) can convert an out-of-network denial into in-network coverage.
Medicaid managed care fair hearings. Centene-managed Medicaid plans (Sunshine Health, Buckeye, Peach State, etc.) operate under each state's Medicaid rules. After plan-level appeal, members have the right to a state fair hearing, a binding administrative process with strong reversal history.

How to win your Centene / Ambetter biologic and infusion therapy appeal

Strategy for biologic and infusion therapy: Get the plan's drug policy and match every criterion to a page in the chart: diagnosis, severity score, prior drugs with dates and outcomes, screening labs, prescriber specialty. Where step therapy is the reason, use the plan's exception process and, where applicable, the state step-therapy law that requires an override when the required drug was tried, is contraindicated, or is expected to be ineffective. For a switch after loss of response, document the objective loss of response. Ask for a peer-to-peer with a reviewer in the same specialty.

Filed against Centene / Ambetter, that strategy rides on this procedural spine:

Procedural-rights anchor. Every Centene / Ambetter denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
Criteria-disclosure demand. Centene / Ambetter frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).
Treating-provider attestation. A letter from the treating physician addressing each criterion in Centene / Ambetter's own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the biologic and infusion therapy denial and approve the service, not a general "please reconsider."

Documents you'll need for your Centene / Ambetter biologic and infusion therapy appeal

The denial letter with the criterion or policy cited
Specialist's notes with diagnosis and disease-activity measures
Prior medication history with dates, doses, and outcomes
TB, hepatitis, and other screening results
The plan's drug policy and formulary exception form

What a biologic and infusion therapy appeal can recover

Typical recovery for biologic and infusion therapy cases runs Biologics are priced in the thousands of dollars per dose; a denied year of therapy is commonly a five-figure sum at billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

Centene / Ambetter biologic and infusion therapy appeals: frequently asked questions

Centene / Ambetter wants me to fail a cheaper drug first. Do I have to?

Not always. Plans must have an exception process, and many states require an override when the required drug was already tried, is contraindicated, or is expected to be ineffective. The prescriber's letter should say which of those applies and why.

Why was my biologic denied when my doctor prescribed it?

Most denials are documentation gaps: a missing severity score, an undocumented prior drug, or a screening lab not on file. The plan's policy tells you exactly which item is missing; request it.

Centene / Ambetter moved my infusions out of the hospital. Can I appeal the site of care?

Yes. Site-of-care denials are appealable. The record needs to show why the hospital setting is medically required, for example prior infusion reactions or complex comorbidities.

Is a biosimilar the same drug?

A biosimilar is highly similar to the reference biologic with no clinically meaningful difference, per FDA. Plans may prefer one. If a switch caused loss of response or an adverse reaction, that history is the basis for an exception.

What Apellica does for Centene / Ambetter biologic and infusion therapy appeals

We file appeals against Centene / Ambetter specifically configured to its internal review process. Every biologic and infusion therapy appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Centene / Ambetter appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your Centene / Ambetter biologic and infusion therapy appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

Centene / Ambetter denied your biologic and infusion therapy? Here is what to do next